Ozone (O₃) is an unstable molecule — it wants to release its third oxygen atom. When it does, it creates reactive oxygen species (ROS) that attack lipid membranes, the outer layer of bacterial cells. Bacteria like Borrelia lack the antioxidant defences that human cells have, which is what makes ozone selectively toxic to pathogens without (at correct doses) causing equivalent damage to healthy tissue.
This page covers the main forms of ozone therapy used in Lyme disease, what research exists, what the therapy involves in practice, and where the real risks lie.
The mechanism behind ozone therapy
Ozone disrupts the phospholipid layer of bacterial cell membranes. This is the same layer that Borrelia — and co-infections like Bartonella and Babesia — depend on for structural integrity. When the membrane is compromised, the cell cannot maintain its internal environment and dies. Crucially, human cells possess enzymatic antioxidant systems (catalase, glutathione peroxidase) that neutralise the reactive oxygen species before they cause the same damage. At correctly calibrated doses, this difference is what gives ozone its selectivity.
Beyond direct bacterial killing, ozone at therapeutic doses stimulates the production of cytokines and activates white blood cells — improving the immune system's own capacity to identify and eliminate pathogens. In chronic Lyme disease, where immune dysfunction is a central feature of persistent symptoms, this immunomodulatory effect may be as important as the direct antimicrobial action.
Lyme disease produces a significant toxic burden — dead bacterial fragments, inflammatory byproducts, and accumulated metabolic waste. Ozone therapy is reported to enhance liver and kidney function and support the clearance of these toxins from the bloodstream. In EBOO (see below), this detoxification occurs directly and continuously during treatment as blood passes through a filtration system.
How ozone is administered
Ozone cannot simply be inhaled or injected directly. It must be introduced into the body in ways that allow it to react safely. Several approaches have developed over the decades, varying in complexity, cost, and depth of effect.
A volume of blood (typically 100–200 ml) is withdrawn from a vein into a sealed bag, mixed with a measured dose of ozone gas, and reinfused intravenously. The ozonated blood carries the reactive oxygen species back into circulation, where they interact with pathogens and stimulate immune response.
A standard course for Lyme disease typically involves 10–20 sessions. Each session takes approximately 45–60 minutes. Sessions are usually spaced 2–3 times per week.
The more intensive form of ozone treatment. Blood is withdrawn continuously through one IV line, passes through an external filtration and ozonation circuit — similar in principle to dialysis — and is returned through a second IV line. Unlike MAH, which treats a fixed volume of blood per session, EBOO processes a much larger volume continuously, filtering out inflammatory byproducts and pathogens as it ozonates.
EBOO is more expensive than MAH and requires a properly equipped clinic. It is increasingly offered at Lyme-specialising integrative practices. A single EBOO session may take 60–90 minutes and is typically part of a series of 5–10 treatments.
Ozone gas is introduced rectally via a catheter, where it is absorbed through the intestinal wall into the portal circulation. Less potent than IV approaches and slower in effect, but accessible as a home protocol for patients who cannot afford or access regular IV sessions. Requires appropriate equipment and correct dosing — incorrectly administered rectal ozone can cause mucosal irritation or infection.
A small volume of blood is withdrawn, irradiated with ultraviolet light, and reinfused. Used historically as an antimicrobial approach and sometimes combined with ozone treatment at integrative clinics. Considerably less common than MAH or EBOO and with a weaker evidence base. Mentioned here for completeness as it appears in some Lyme clinic protocols.
Evidence — and where it currently stands
As of early 2026, ozone therapy for Lyme disease has been studied in laboratory models and animal studies, but no completed human clinical trials exist. This is a meaningful distinction. Lab and animal results are promising — but they do not guarantee the same effects in humans, where pharmacokinetics, tissue distribution, and immune complexity all differ substantially.
The Global Lyme Alliance has funded research at Tufts University (Dr. Tanja Petnicki-Ocwieja) specifically investigating ozone's effects on Lyme bacteria and the inflammatory response. This represents the first targeted scientific attention to the question at a reputable institution. Results have not yet been published at time of writing.
In vitro studies show that reactive oxygen species generated by ozone damage the outer membrane lipopolysaccharides of gram-negative bacteria — a category that includes Borrelia. The mechanism is biologically plausible and has been confirmed for other spirochetes. The challenge is translating petri-dish concentrations to therapeutically relevant, safely delivered doses in humans.
Clinical practitioners working with Lyme patients report consistent subjective improvement in fatigue, cognitive symptoms, and pain following ozone courses — often described as "clearing" that occurs after initial Herxheimer worsening. These accounts are widespread and come from practitioners on multiple continents. They are not substitutes for clinical trial data, but they are not nothing either. They describe a consistent pattern that is worth understanding honestly rather than dismissing.
What can go wrong — and what must be understood first
Ozone is toxic to lung tissue at any therapeutic concentration. Inhalation — even brief, even accidental — can cause severe pulmonary irritation and lasting damage. Every reputable ozone practitioner works with closed systems. If any protocol involves breathing ozone, it is not a legitimate ozone therapy.
- Herxheimer reaction — particularly with EBOO, a significant die-off of bacteria can trigger a Herx response: intensified fatigue, aches, and cognitive symptoms in the days following treatment. This is expected and manageable with hydration and rest, but patients with severe illness should start at low doses.
- Vein irritation — IV ozone therapy involves repeated venepuncture. Vein irritation, bruising, and occasionally mild phlebitis can occur. Experienced practitioners minimise this through correct technique and alternating injection sites.
- Incorrect dosing — ozone concentration and volume must be calibrated precisely per patient. Too much ozone applied too quickly can overwhelm detoxification pathways and cause symptoms beyond normal Herx. Dose titration at the start of a course is standard practice.
- Rectal route infections — improperly performed rectal insufflation can introduce infection. Sterile equipment and correct technique are non-negotiable.
- Unqualified practitioners — ozone therapy has attracted practitioners without appropriate training. Look for clinics with documented medical oversight, calibrated medical-grade generators, and explicit protocols. The quality of administration matters as much as the therapy itself.
- No approved indication — ozone therapy for Lyme disease is used entirely off-label in all countries. This is not inherently disqualifying, but it means there is no regulatory standard of care to fall back on if something goes wrong.
Ozone vs HBOT — different tools, shared logic
Both ozone therapy and hyperbaric oxygen work by creating oxidative conditions hostile to Borrelia. The practical differences matter when choosing between them.
HBOT has more clinical data — a cohort study with 91 patients and several documented case reports. Ozone has promising laboratory evidence and substantial clinical practitioner experience, but no completed human trials for Lyme specifically. If clinical validation matters to you, HBOT is the more documented path.
A full HBOT course (40 sessions) can cost €4,000–€8,000 and requires access to a clinical-grade chamber. MAH ozone is typically €80–€150 per session; a course of 15–20 sessions costs significantly less. EBOO is more expensive but still below HBOT for a full course. For patients where cost is a barrier, ozone may be the more accessible oxidative approach.
HBOT has a more direct and documented effect on neurological Lyme specifically — it crosses the blood-brain barrier via dissolved plasma oxygen and has shown changes in SPECT brain imaging. For patients with significant neurological symptoms (brain fog, cognitive impairment, neuropathy), HBOT may be the more targeted choice if it is accessible.
Other approaches in this section
Hyperbaric oxygen therapy has the strongest clinical evidence of the oxygen-based approaches. If you haven't read that page yet, it provides a useful reference point for comparing evidence quality.
Healing mentality checkpoint
Oxidative therapies — ozone and HBOT alike — can be powerful. They can also trigger significant Herx reactions that temporarily make you feel worse before you feel better. Going into any of these protocols without understanding that dynamic, and without support in place, is how people abandon treatments that might have eventually helped.
Read about healing mentality →Sources & further reading
- Global Lyme Alliance — Ozone therapy for Lyme disease: exploring an alternative approach (globallymealliance.org)
- Petnicki-Ocwieja T. — GLA-funded ozone research, Tufts University (in progress as of 2024–2026)
- Charleston Pain Relief Center — EBOO therapy and Lyme disease recovery (2025)
- Lantos P.M. et al. — Unorthodox alternative therapies marketed to treat Lyme disease, Clinical Infectious Diseases (2015) — for critical perspective
- ILADS clinical guidelines — ilads.org
Last updated: March 2026